Bridgebio Pharma Stock Price, News & Analysis

BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases and cancers, will host its first R&D Day on September 29 at 8:30 am E.T. The virtual event will showcase presentations from BridgeBio's leadership and external experts. Key focus areas include the company’s drug engineering platform and targeted oncology portfolio, with four highlighted programs expected to present clinical data in the next 12-24 months: acoramidis for transthyretin amyloidosis, low-dose infigratinib for achondroplasia, AAV5 gene therapy for congenital adrenal hyperplasia, and encaleret for autosomal dominant hypocalcemia type 1.

BridgeBio Pharma's affiliate, Calcilytix Therapeutics, has initiated a Phase 2 study for encaleret (CLTX-305), targeting ADH1, a rare genetic condition causing low serum calcium levels. The study, conducted at the NIH, aims to enroll 16 participants to assess the drug’s safety and efficacy. Currently, there are no approved treatments for ADH1, with conventional therapies often exacerbating symptoms. Topline proof-of-concept results are anticipated in 2021, aiming to address significant unmet medical needs for patients suffering from this debilitating disorder.

BridgeBio Pharma (Nasdaq: BBIO) announced on September 1, 2020, the granting of options to purchase 18,231 shares and restricted stock units for 19,915 shares under its 2019 Inducement Equity Plan. The compensation committee made these grants to 10 new employees as an inducement for their employment, adhering to Nasdaq Listing Rule 5635(c)(4). These awards are part of BridgeBio's effort to attract talent as it advances its pipeline of over 20 programs targeting genetic diseases and cancers with genetic drivers.

BridgeBio Pharma (Nasdaq: BBIO) announced the grant of stock options and restricted stock units to 22 employees on August 3, 2020. The total awards comprise options for 30,443 shares and restricted units for 61,760 shares, with an exercise price of $27.20 per share. These grants are part of the 2019 Inducement Equity Plan, established to incentivize new employees under Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases, holding a diverse pipeline of over 20 programs.

BridgeBio Pharma (Nasdaq: BBIO) reported second-quarter results for 2020, achieving significant milestones in its clinical pipeline and collaborations. The company initiated four clinical trials and submitted three IND applications to the FDA, with a reported cash position of $840.9 million as of June 30, 2020. BridgeBio expanded its global presence through a partnership with LianBio, focusing on oncology, with potential payments of $26.5 million upfront and up to $505 million in future milestones. Operating expenses increased to $124.6 million, resulting in a net loss of $136.2 million for the quarter.

BridgeBio Pharma (NASDAQ: BBIO) announces a strategic partnership with LianBio to expand its presence in China, a significant pharmaceutical market. The collaboration involves initial $26.5 million in payments and potential future milestones of up to $505 million. It focuses on the development of FGFR inhibitor infigratinib and SHP2 inhibitor BBP-398 for cancers with genetic mutations. BridgeBio aims to address patient needs in Asia by leveraging LianBio's local access and expertise. CEO Neil Kumar joins LianBio's board, reinforcing their partnership.

BridgeBio Pharma announced that the first patient has been dosed in a Phase 0/2 clinical trial of infigratinib, an investigational drug targeting FGFR genetic alterations in recurrent high-grade glioma patients. This trial aims to confirm the drug’s effectiveness in crossing the blood-brain barrier and hitting molecular targets. Patients showing positive pharmacokinetic responses will continue treatment post-surgery. The primary endpoint is a six-month progression-free survival rate. FGFR alterations are present in 5-7% of glioblastoma cases, highlighting the drug's potential impact.

BridgeBio Pharma's affiliate, QED Therapeutics, has initiated the PROPEL 2 Phase 2 clinical trial, dosing the first child with achondroplasia using infigratinib, an oral medicine targeting FGFR3. This trial aims to assess safety and measure height growth impact. Preclinical data show potential for significant growth improvement. CEO Michael Henderson emphasized the trial's significance, highlighting the extensive preparatory work. Infigratinib operates as a selective tyrosine kinase inhibitor, and the trial follows previous assessments demonstrating its efficacy at lower doses.

BridgeBio Pharma's affiliate, Phoenix Tissue Repair, announced the presentation of interim safety and tolerability data from a Phase 1/2 trial for PTR-01, a recombinant collagen 7 therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). The results will be shared virtually during the Society for Pediatric Dermatology’s Annual Meeting from July 10-12, 2020. PTR-01 has previously shown promising preclinical results, with Orphan Drug Designation granted by the FDA and EMA. Currently, no approved therapies exist for DEB, and the standard care is limited to wound management.